

**Lifestyle risk factors and infectious disease mortality, including COVID-19, among middle aged and older adults: Evidence from a community-based cohort study in the United Kingdom**

Matthew N. Ahmadi <sup>1</sup>

Bo-Huei Huang <sup>1</sup>

Elif Inan-Eroglu <sup>1</sup>

Mark Hamer <sup>2</sup>

Emmanuel Stamatakis <sup>1</sup>

1) Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, NSW, Australia

2) Division of Surgery and Interventional Science, Faculty Medical Sciences, University College London, London, UK

**Corresponding Author:**

Matthew N. Ahmadi

Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health  
Level 6, 1 John Hopkins Drive  
Camperdown, NSW 2006  
Australia

Phone: +61 2 86278646

Email: [matthew.ahmadi@sydney.edu.au](mailto:matthew.ahmadi@sydney.edu.au)

Word count: 4204

## 1 **Abstract**

2 In this community-based cohort study, we investigated the relationship between combinations  
3 of modifiable lifestyle risk factors and infectious disease mortality. Participants were 468,569  
4 men and women ( $56.5 \pm 8.1$ , 54.6% women) residing in the United Kingdom. Lifestyle indexes  
5 included traditional and emerging lifestyle risk factors based on health guidelines and best  
6 practice recommendations for: physical activity, sedentary behaviour, sleep quality, diet  
7 quality, alcohol consumption, and smoking status. The main outcome was mortality from  
8 infectious diseases, including pneumonia, and coronavirus disease 2019 (COVID-19). Meeting  
9 public health guidelines or best practice recommendations among combinations of lifestyle risk  
10 factors was inversely associated with mortality. Hazard ratios ranged between 0.26 (0.23-0.30)  
11 to 0.69 (0.60-0.79) for infectious disease and pneumonia. Among participants with pre-existing  
12 cardiovascular disease or cancer, hazard ratios ranged between 0.30 (0.25-0.34) to 0.73 (0.60-  
13 0.89). COVID-19 mortality risk ranged between 0.42 (0.28-0.63) to 0.75 (0.49-1.13). We  
14 found a beneficial dose-response association with a higher lifestyle index against mortality that  
15 was consistent across sex, age, BMI, and socioeconomic status. There was limited evidence of  
16 synergistic interactions between most lifestyle behaviour pairs, suggesting that the dose-  
17 response relationship among different lifestyle behaviours is not greater than the sum of the  
18 risk induced by each behaviour. Improvements in lifestyle risk factors and meeting public  
19 health guidelines or best practice recommendations could be used as an ancillary measure to  
20 ameliorate infectious disease mortality.

21 **Keywords:** Physical activity, sedentary behaviour, sleep, diet, alcohol, smoking, population  
22 cohort

## 23 **1. Introduction**

24 The increase in annual infectious disease cases and the proliferation of resistant strains of  
25 pathogens threatens the successful treatment of community acquired infections (Cassini et al.,  
26 2019; Marston et al., 2016; Tacconelli et al., 2018). An additional 60,900 deaths occur annually  
27 due to antimicrobial resistance across the United States and Europe, whilst the incidence of  
28 sepsis now exceeds 48 million cases worldwide (Gelband et al., 2015; Kadri, 2020; Rudd et  
29 al., 2020). Respiratory infections, such as pneumonia, are the leading cause of death in  
30 developing countries, and the largest contributor to the overall burden of disease in the world  
31 measured in disability adjusted life years (Ferkol and Schraufnagel, 2014; Nair et al., 2011).  
32 Among the detrimental effects of infectious diseases are significant decreases in quality of life  
33 for individuals, in addition to clinical and economic burden across communities. The direct  
34 costs of treating community acquired pneumonia is estimated to be between 3.7 to 12.1 billion  
35 USD annually, with an additional \$1.8 to \$3.6 USD billion in indirect costs of economic  
36 productivity losses (Song et al., 2011; Welte et al., 2012; Weycker et al., 2010). Most recently,  
37 severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019  
38 (COVID-19) has led to a global health pandemic.

39 Severe progression of infectious diseases is associated with multiple lifestyle risk factors (Baik  
40 et al., 2000; Hamer et al., 2019). The role of lifestyle behaviours and risk of infectious disease  
41 mortality is becoming increasingly important. This requires a better understanding of the  
42 relationship between combinations of different lifestyle risk factors that may increase the risk  
43 of mortality. To date, studies have only examined the individual associations of lifestyle risk  
44 factors and infectious diseases (Hamer et al., 2019; Paulsen et al., 2017; Wang et al., 2017).  
45 For example, smokers have shown an increased risk of both bacterial and viral infection-related  
46 mortality (Carter et al., 2015; Huttunen et al., 2011), and poor diet quality has been associated

47 with low resistance to infections (Ambrus and Ambrus, 2004; Gordon, 1968; Katona and  
48 Katona-Apte, 2008; Scrimshaw and SanGiovanni, 1997). Further, among individuals, who  
49 never drink alcohol or moderately drink, infectious disease risk does not differ; risk, however,  
50 increases substantially among heavy drinkers, leading to higher rates of morbidity and  
51 mortality (Rehm et al., 2010; Samokhvalov et al., 2010). Higher volumes of physical activity  
52 are associated with a lower incidence of infectious diseases and related mortality (Baik et al.,  
53 2000; Hamer et al., 2019). Most recently, physical inactivity, a history of smoking, and  
54 excessive alcohol consumption have been identified as lifestyle risk factors that contribute to  
55 increased risk of hospitalizations due to COVID-19. More than a 4-fold increase in  
56 hospitalisation was observed among participants engaging in all unfavourable behaviours  
57 (Hamer et al., 2020). The additive influence of multiple lifestyle behaviours against infection  
58 related mortality, remains unknown.

59 Prior literature suggests different lifestyle behaviours may have synergistic effects (Stamatakis  
60 et al., 2015; Xiao et al., 2014). The risk of immune-suppressive effects from an unhealthy  
61 lifestyle behaviour, such as physical inactivity, may be amplified by unhealthy sleep habits and  
62 high sedentary time. Among the possible consequences is an increased risk of hospitalisations  
63 and mortality events caused by respiratory infections (Fletcher et al., 2018; Ibarra-Coronado et  
64 al., 2015; Nieman et al., 2011; Opp and Krueger, 2015; Sallis et al., 2020). Studies that have  
65 observed inconsistent relationships between inadequate sleep duration and respiratory  
66 infections did not consider the role of sleep quality or the influence of combined lifestyle  
67 behaviours (Irwin, 2015; Prather and Leung, 2016). Considering that individual lifestyle risk  
68 factors may have an additive influence on mortality risk, investigating combinations of lifestyle  
69 behaviours together will elucidate more clinically relevant information (Ding et al., 2015;  
70 Dunstan et al., 2012; Hamer et al., 2014; Hamilton et al., 2007; Stamatakis et al., 2015).

71 To our knowledge, no studies have examined the associations between both established and  
72 emerging lifestyle risk factors, with infectious disease that include: physical activity, sedentary  
73 behaviour, sleep quality, diet quality, alcohol consumption, and smoking status. The aim of  
74 this study was to examine the association of combined lifestyle risk factor indexes and risk of  
75 infectious disease mortality, including mortality due to pneumonia and COVID-19.

## 76 **2. Materials and Methods**

### 77 **2.1 Participants**

78 The UK Biobank is a prospective cohort study which aims to investigate the genetic, lifestyle,  
79 and environmental causes of a range of diseases (Allen et al., 2012; Sudlow et al., 2015; UK  
80 Biobank, 2007). Between 2006 and 2010, 502,656 adults aged between 40 and 69 years  
81 (229,182 men and 273,474 women) were recruited. All participants were registered with the  
82 UK National Health Service (NHS) and lived within ~40 km of 1 of the 22 study assessment  
83 centres. The UK Biobank invited ~9.2 million people to participate through postal invitation  
84 with a telephone follow-up, with a response rate of 5.7%. The UK Biobank has approval from  
85 the North West Multi-Centre Research Ethics Committee, the National Information  
86 Governance Board for Health and Social Care in England and Wales, and the Community  
87 Health Index Advisory Group in Scotland. In addition, an independent Ethics and  
88 Governance Council was formed in 2004 to oversee UK Biobank's continuous adherence to  
89 the Ethics and Governance Framework, which were developed for the study ([http://www.uk-](http://www.uk-biobank.ac.uk/ethics/)  
90 [biobank.ac.uk/ethics/](http://www.uk-biobank.ac.uk/ethics/)). All participants provided written informed consent.

91 Participants consented to the use of their de-identified data and access to their national health-  
92 related hospital and death records. Exclusions prior to the onset of analyses included  
93 participants who did not have complete/usable physical activity, sedentary behaviour, sleep,

94 diet, alcohol consumption, and smoking history information (n =20,144). We then excluded  
95 any remaining participants with an incomplete covariate profile (n = 13,903).

## 96 **2.2 Measurements**

97 During the baseline recruitment visit, participants were asked to complete a self-administered  
98 touchscreen questionnaire, which included questions on socio-demographics and lifestyle  
99 exposures.

100 **2.2.1 Physical activity:** Physical activity was measured using the International Physical  
101 Activity Questionnaire (IPAQ) short form (Craig et al., 2003) and included items on  
102 frequency and duration of walking, moderate intensity activity, and vigorous intensity  
103 activity. Missing values for a category were imputed using multivariate imputation by  
104 chained equations (Buuren and Groothuis-Oudshoorn, 2010). Physical activity was expressed  
105 as MET-hrs/week and based on the IPAQ scoring procedure, participants who attained 600  
106 MET-hrs/week met the physical activity guidelines of 150 minutes of moderate-vigorous  
107 physical activity a week (Bull et al., 2020). Participants were classified as inactive if they  
108 attained 0 MET-hrs/week, insufficiently active if they had less than 600 MET-hrs/week, and  
109 sufficiently active if they had at least 600 MET-hrs/week.

110 **2.2.2 Sedentary time:** Total sedentary time was based on three questions enquiring about  
111 daily hours of TV, PC screen-based activities and driving. Sedentary time was classified as  
112 high (> 7 hours/d), medium (4 to 7 hours/d) , or low (>=4 hours/d).(Chau et al., 2015, 2013)

113 **2.2.3 Sleep quality:** Sleep quality was assessed using five healthy sleep characteristics which  
114 included (Fan et al., 2020): Morning chronotype, sleep duration (7-9 hours), not usually  
115 insomnia, no snoring, and no frequent daytime sleepiness. Following the sleep quality scoring  
116 by Fan et al, participants were given a score of “1” for every question they answered “yes”  
117 (Fan et al., 2020). Component scores were summed and participants were classified as having

118 poor sleep quality (score = 0 to 1), moderate sleep quality (score = 2 to 3), or good sleep  
119 quality (score = 4 to 5).

120 **2.2.4 Diet Quality:** Diet quality was assessed using a modified Alternate Healthy Eating  
121 Index (AHEI), which is based on foods and nutrients that have been shown to be predictive of  
122 disease (Chiuve et al., 2012). Participants are given a score of 0 to 10 for each food category  
123 and the scoring criteria for the AHEI is described in detail elsewhere (McCullough et al.,  
124 2002). For the current study, participants reported their daily diet in four categories: fruits,  
125 vegetables, whole grains, and portions of red meat/ processed meat. All the component scores  
126 were summed and participants were classified as having poor diet quality (score = 0 to 10),  
127 moderate diet quality (score = 11 to 30), and good diet quality (score = 31 to 40).

128 **2.2.5 Alcohol consumption:** Participants reported their alcohol drinking status as: Never  
129 drinker, ex-drinker, or current drinker. Participants who were current drinkers, were asked  
130 about average weekly consumption of wine, spirits, and beer intake. Based on current UK  
131 guidelines, participants were categorised as never drinkers, ex-drinkers, within guideline  
132 drinkers (<14 UK units of alcohol/wk; 1 unit = 8g of alcohol), or above guideline drinkers  
133 ( $\geq 14$  UK units of alcohol/wk).(Health, 2016; Rosenberg et al., 2018)

134 **2.2.6 Smoking status:** Participants were asked to report their current smoking status. They  
135 were classified as never smokers, previous smokers, and current smokers.

136 **2.2.7 Healthy Lifestyle Index:** Each lifestyle behaviour, except for alcohol consumption,  
137 was assigned a score ranging from zero (least healthy behaviour) to two (most healthy  
138 behaviour). Alcohol consumption was categorized into four groups on the basis that ex-  
139 alcohol drinkers are generally at a higher risk of all-cause mortality than lifelong never  
140 drinkers (Knott et al., 2015; Perreault et al., 2017).

141 Table 1 describes the categorisation for all six lifestyle risk factors and the corresponding  
142 scores that were assigned to participants. All six individual lifestyle behaviour scores were  
143 added together to obtain a healthy lifestyle index score. Never drinkers and guideline drinkers  
144 were given the same index score because the behaviours have both been shown to have  
145 similar protective health benefits (Friedman and Klatsky, 1993). A lifestyle behaviour score  
146 of 0-4 represented the least healthy group and was an indication that participants had a score  
147 of 0 in multiple behaviour categories without a score of 2 in more than two categories. A  
148 score of 10-12 represented the healthiest group, and was an indication that participants had a  
149 score of 2 in at least four out of the six categories.

150 --Insert Table 1 near here--

## 151 **2.3 Outcomes**

152 Participant data was linked to the national datasets from the National Health Service (NHS)  
153 Information Centre (England and Wales) and the NHS Central Register Scotland (Scotland).  
154 Complete follow-up was available through June 28<sup>th</sup>, 2020. Mortality incidence data were  
155 coded using the 10<sup>th</sup> Revision of the International Classification of Diseases (ICD-10) and  
156 included if it was the underlying or contributory cause of death. Infectious disease mortality  
157 was identified using the following ICD-10 codes: A00-B99 and J09-J18 (pneumonia).  
158 COVID-19 mortality was identified using ICD-10 codes U07.1-U07.2.

## 159 **2.4 Statistical analyses**

160 Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox  
161 proportional hazards regression models for individual lifestyle risk factors and healthy  
162 lifestyle index with infectious disease outcome. The reference group for each individual  
163 lifestyle risk factor was the least favourable lifestyle behaviour. The timescale was in  
164 calendar time (months). Multivariable proportional regression models were adjusted for the



165 following covariates: age at baseline, sex, socioeconomic status based on the Townsend  
166 deprivation index (Townsend et al., 1988), ethnicity (White, South Asian, Black, Chinese,  
167 and other), body mass index (weight divided by squared height), corticosteroid use, and  
168 comorbidities (cardiovascular diseases, cancers, diabetes, chronic respiratory disease [ICD-10  
169 codes J.40 to J.47], liver disease, end-stage renal disease, immune disorders/HIV, and  
170 hypertension defined as  $\geq 140/90$  mmHg)

171 To examine the associations between individual lifestyle risk factors and healthy lifestyle  
172 index with COVID-19 mortality, we used binomial regression to account for all mortality  
173 events occurring only between March to June 2020. The adjusted risk ratio models included  
174 all the covariates previously listed.

175 To evaluate the consistency of our findings in different population subgroups, we conducted a  
176 set of stratified analysis by: sex (male; female); age ( $< 50$  years;  $< 60$  years; and  $\geq 60$  years);  
177 body mass index (BMI) category (normal weight; overweight; obese); and socioeconomic  
178 status (Townsend index quintiles). In addition, we examined the associations among  
179 participants who had a history of cardiovascular disease and cancer. Three measures were  
180 used to investigate interaction between pairs of lifestyle behaviours: The relative excess risk  
181 due to interaction (RERI); attributable proportion due to interaction (AP); and the synergistic  
182 effects (S). RERI and AP would be equal to zero and S would be equal to 1 if there is no  
183 interaction present between pairs of behaviours (Andersson et al., 2005; Källberg et al.,  
184 2006). To reduce the possibility of spurious associations due to reverse causation, we  
185 repeated analyses after excluding all participants who died in the first five years of follow-up.  
186 Sensitivity analysis was conducted for infectious disease mortality by excluding all infectious  
187 disease mortality due to pneumonia. In another set of sensitivity analyses, we excluded  
188 participants with a history of smoking, cardiovascular disease, and cancer and included self-  
189 reported health as a covariate. We also assessed the associations of individual lifestyle risk

190 factors with mortality among participants who had the least healthy lifestyle index score. All  
191 analysis was performed using R software (version 4.0.2).

## 192 **3. Results**

### 193 **3.1 Sample**

194 Our analysis included 468,569 participants. Supplemental Figure 1 provides a detailed  
195 flowchart of participants who were excluded due to missing or unusable data. The  
196 participants included in the study had a corresponding 4,176 deaths due to infectious diseases  
197 and 3,170 deaths due to pneumonia. There were an additional 387 deaths due to COVID-19.  
198 The number of participants with an event for each type of infectious disease is listed in  
199 Supplemental Table 1. The absolute risk and person-time rate for each healthy lifestyle index  
200 category is displayed in Supplemental Table 13. Table 2 presents the characteristics of the  
201 population at baseline. The median follow-up time was 11.3 years (IQR: 10.5 to 11.9 years)  
202 with a total of 5,166,793 person-years of follow-up before death or censoring, and 54.6% of  
203 the participants were female. The average age of participants at baseline was 56.5 ( $\pm$  8.1)  
204 years. Among the 29,281 participants classified as having the lowest healthy lifestyle  
205 behaviour index score (0 to 5 score), 62.7% were inactive, 41.9% reported more than 7 hours  
206 per day in discretionary sedentary time, and 14.4% had poor sleep quality. Among these  
207 participants, 53.8% had poor diet quality, 45.8% were current smokers, and 87.3% were ex-  
208 drinkers or consuming more than 14 units of alcohol per week. Healthy lifestyle behaviour  
209 index scores were more prevalent among females, those with lower body mass index, and  
210 higher socioeconomic status.

211 --Insert Table 2 near here--

## 212 3.2 Individual lifestyle risk factors

213 **3.2.1 Infectious disease and pneumonia mortality:** The hazard ratios of each individual  
214 lifestyle behaviour for infectious disease and pneumonia mortality are provided in Tables 3  
215 and 4, respectively. In the fully adjusted models, we found a direct association between all  
216 three movement behaviours (physical activity, sedentary behaviour, sleep) and infectious  
217 disease mortality and pneumonia mortality. When individuals with good sleep quality were  
218 compared to individuals with poor sleep quality, we observed a 20% decrease in infectious  
219 disease mortality (HR [95% CIs]: 0.80 [0.70 to 0.92]) and pneumonia mortality (0.80 [0.68 to  
220 0.95]). The associations for sedentary time followed the same pattern, and when individuals  
221 with low sedentary time were compared to individuals with high sedentary time, we observed  
222 ≈21% decrease in infectious disease mortality (0.78 [0.72 to 0.87]) and pneumonia mortality  
223 (0.79 [0.67 to 0.94]). Comparatively, when individuals who were sufficiently active were  
224 compared to those who were inactive, we observed a 37% decrease in infectious disease  
225 mortality (0.64 [0.59 to 0.69]) and pneumonia mortality (0.63 [0.58 to 0.69]) (Tables 3 and  
226 4).

227 Individuals who were ex-smokers or had never smoked had a significantly lower risk for  
228 infectious disease mortality (ex-smokers: 0.50 [0.46 to 0.54]; never smokers: 0.37 [0.34 to  
229 0.41]) and pneumonia mortality (ex-smokers: 0.46 [0.42 to 0.51]; never smokers: 0.33 [0.30  
230 to 0.36]) compared to individuals who were current smokers. In contrast, there was weak  
231 evidence for an association of diet quality. Compared to those with the poorest diet quality  
232 (referent group), only participants with good diet quality had an attenuated risk for infectious  
233 disease mortality (0.85 [0.77 to 0.93]) and pneumonia mortality (0.82 [0.75 to 0.91]). When  
234 ex-drinkers (referent group) were compared to current drinkers we observed a 44% to 47%  
235 reduction in infectious disease mortality (within guideline drinkers: 0.56 [0.50 to 0.63]; above  
236 guideline drinkers: 0.53 [0.47 to 0.60]).

237

--Insert Tables 3 and 4 near here--

238 **3.2.2 COVID-19 mortality:** Table 5 shows the risk ratio of each lifestyle behaviour category  
239 for COVID-19 mortality. In the fully adjusted models, individuals who were sufficiently  
240 active (RR [95% CIs]: 0.70 [0.54 to 0.89]), had never smoked (0.54 [0.39 to 0.74]), and were  
241 current drinkers (within guideline drinkers: 0.60 (0.40 to 0.89); above guideline drinkers:  
242 0.62 [0.41 to 0.93]) had lower COVID-19 mortality risk compared to the referent groups of  
243 each lifestyle risk factor.

244

--Insert Table 5 near here--

### 245 **3.3 Healthy lifestyle index**

246 **3.3.1 Infectious disease and pneumonia mortality:** Figure 1 shows the healthy lifestyle  
247 index hazard ratios for infectious disease and pneumonia mortality. For both infectious  
248 disease and pneumonia, there was a dose-response association with higher lifestyle index  
249 scores. For example, there was a 34% (HR [95% CIs]: 0.66 [0.59 to 0.75]) to 71% (0.29 [0.26  
250 to 0.33]) reduction in infectious disease mortality for participants who were not classified in  
251 the least healthy behaviour group. Similarly, the pneumonia mortality risk was gradually  
252 attenuated with a higher lifestyle index; e.g. a 31% (0.69 [0.60 to 0.79]) to 74% (0.26 [0.23 to  
253 0.30]) lower pneumonia mortality risk for participants when compared to those in the least  
254 healthy behaviour group. Additional analysis for infectious disease and pneumonia among  
255 only participants with cancer or cardiovascular disease showed a dose-response association  
256 with higher lifestyle index scores (Supplemental Figure 2 and 3). For infectious disease,  
257 participants with cancer had a 28% (0.72 [0.60 to 0.86]) to 65% (0.35 [0.29 to 0.42])  
258 reduction in mortality risk, whilst participants with cancer had a 30% (0.72 [0.61 to 0.79]) to  
259 68% (0.32 [0.28 to 0.37]) reduction compared to participants classified in the least healthy  
260 behaviour group. Likewise, the pneumonia mortality risk among was gradually attenuated

261 with a higher lifestyle index; participants with cancer had a 27% (0.73 [0.60 to 0.89]) to 69%  
262 (0.31 [0.25 to 0.38]) reduction in mortality risk, and participants with cardiovascular disease  
263 had a 29% (0.71 [0.61 to 0.82]) to 70% (0.30 [0.25 to 0.34]) reduction.

264 --Insert Figure 1 near here --

265 **3.3.2 COVID-19 mortality:** Figure 2 displays the healthy lifestyle index risk ratios for  
266 COVID-19 mortality. Across the lifestyle groupings, we observed a similar reduction for  
267 COVID-19 mortality risk as in infectious disease and pneumonia mortality above. Among the  
268 4<sup>th</sup> healthiest to healthiest lifestyle index, COVID-19 mortality risk was attenuated by 44%  
269 (RR [95% CIs]: 0.56 [0.38 to 0.82]) to 58% (0.42 [0.28 to 0.63]) for individuals who were  
270 not classified in the least healthy behaviour group.

271 --Insert Figure 2 near here --

272 **3.3.3 Population impact:** Supplemental Tables 2 to 11 and Supplemental Figures 2 to 3  
273 display results stratified by sex, age, body mass index, socioeconomic status, and participants  
274 diagnosed with cardiovascular disease or cancer. There were generally consistent dose-  
275 response patterns with higher lifestyle indexes across all strata, including participants in the  
276 highest mortality risk groups. For example, participants in the lowest socioeconomic status  
277 quintile had an infectious disease mortality risk between 0.74 [0.59 to 0.92] to 0.31 [0.24 to  
278 0.40]. Mortality risk among participants who were obese or over 60 years, and not classified  
279 in the lowest lifestyle index category was markedly low; among these participants, hazard  
280 ratios were between 0.70 [0.57 to 0.86] to 0.31 [0.20 to 0.47] for infectious disease mortality.  
281 Likewise, participants diagnosed with cardiovascular disease or cancer had an incremental  
282 decrease for mortality risk as the healthy lifestyle index improved with hazard ratios between  
283 0.72 [0.60 to 0.85] to 0.32 [0.28 to 0.37]. The only pair of lifestyle behaviours that showed a  
284 statistically significant synergistic interaction (Supplemental Table 12) was not meeting

285 physical activity guidelines and being a current smoker (RERI [95% CI] = 0.4 [0.06-0.8]; S =  
286 1.3 [1.1-1.5], attributable portion due to interaction= 14.0% (2.8%-25.2%)). The lack of  
287 significant synergistic interactions among most lifestyle behaviour pairs suggests that the  
288 dose-response relationship among the different lifestyle behaviours is not greater than the  
289 sum of the risk induced by each behaviour.

290 **3.3.4 Sensitivity analysis:** Removing participants with an event occurring in the first five  
291 years of follow-up, a history of smoking, cardiovascular disease, or cancer had no material  
292 impact on the dose-response associations with infectious disease mortality (Supplemental  
293 Tables 14 and 15, and Supplemental Figures 4 and 5). The associations of individual lifestyle  
294 risk factors with infectious disease mortality were not appreciably different when participants  
295 who had the least healthy lifestyle behaviour index score were analysed separately  
296 (Supplemental Tables 16 and 17). Three of the individual lifestyle risk factors showed  
297 beneficial associations against infectious disease mortality when pneumonia events were  
298 excluded: engaging in at least some physical activity; not being a current smoker; and  
299 consuming at least some alcohol (Supplemental Table 18).

## 300 **4. Discussion**

301 In this prospective cohort study, we examined the additive relationship between multiple  
302 lifestyle risk factors - physical activity, sedentary behaviour, sleeping quality, diet quality,  
303 alcohol consumption, and smoking. We found a clear beneficial dose response association  
304 with a healthier lifestyle index score against mortality from infectious disease, pneumonia,  
305 and COVID-19. These associations were independent of multiple markers of overall health  
306 status. We found limited evidence of synergistic interactions between pairs of behaviours,  
307 suggesting that any beneficial associations conferred by different lifestyle behaviours is not  
308 greater than the sum of the risk induced by each behaviour. This interpretation is supported

309 by the results of the individual risk factors and outcomes. Results for COVID-19 mortality  
310 were consistent, although the low number of events made the statistical comparisons less  
311 clear. The patterns of attenuation, however, were comparable to infectious disease and  
312 pneumonia mortality. Our results are encouraging, not least for middle-aged and older adults  
313 who are at the highest risk of mortality from respiratory infections, who can potentially gain  
314 protection against the consequences of infectious disease through modifiable lifestyle  
315 behaviours.

316 We observed a dose-response for infectious disease mortality with higher lifestyle index  
317 scores. Infectious disease mortality in a smaller analysis of the Health Survey for England  
318 and Scottish Health Survey examining traditional lifestyle behaviours- that included physical  
319 activity, smoking, and alcohol consumption- reported protective associations against  
320 mortality among 97,844 participants if they engaged in at least some moderate to vigorous  
321 physical activity, and had never smoked (Hamer et al., 2019). The study did not examine the  
322 additive effects of lifestyle risk factors that led to a decrease in infectious disease mortality  
323 risk. Analysis of 64,027 HUNT Study participants showed that bloodstream-specific  
324 infectious disease mortality was associated with individual health behaviours, specifically  
325 moderate to vigorous physical activity levels and smoking status (Paulsen et al., 2017). Other  
326 epidemiological studies have assessed other traditional individual behaviours with infectious  
327 disease using various lifestyle behaviour measures (Almirall et al., 2008; Inoue et al., 2007;  
328 Wang et al., 2014). The current study is the first to examine the protective benefits for a  
329 combined healthy lifestyle and among individuals with comorbidities, who are most at risk of  
330 infectious disease mortality. The health benefits were found to be additive and can be attained  
331 through a combination of lifestyle behaviours. The dose-response nature of the associations  
332 between healthy lifestyle indexes was consistent across infectious disease, pneumonia, and  
333 COVID-19 mortality.

334 We found consistent beneficial associations for all six individual lifestyle behaviour  
335 categories with infectious disease and pneumonia mortality. With only one exception,  
336 however, there was no evidence of synergistic interactions between pairs of behaviours.  
337 Specifically, meeting physical activity guidelines and not being a current smoker were the  
338 only lifestyle behaviours to have a synergistic interaction against the risk of infectious disease  
339 mortality. Habitual moderate to vigorous physical activity enhances a number of immune  
340 parameters such as increasing natural killer cell activity, neutrophils, number of circulating  
341 lymphocytes, and cytokine production (Mackinnon, 1999; Matthews et al., 2002; Nieman,  
342 1994; Nieman et al., 1990). Conversely, smoking affects many of the same immune-  
343 parameters but in the opposite direction (Hersey et al., 1983; Sopori, 2002).

344 Meeting health guidelines or best practice recommendations in combinations of different  
345 lifestyle behaviours can significantly reduce the risk of infectious disease mortality among  
346 both the low and high risk segments of the population, regardless of sex, age, weight, or  
347 socioeconomic status. In addition to preventive immunology measures, public health efforts  
348 focused on improvements in meeting minimum lifestyle recommendations could be used as  
349 an ancillary measure to ameliorate the most severe health consequences of infectious disease,  
350 especially among middle aged and older adults. Participants with existing chronic conditions  
351 such as cardiovascular disease and cancer— for whom our study has also shown to gain  
352 health benefits—might choose to engage in a number of differing healthy lifestyle behaviours  
353 and can still attain protective benefits against infectious disease, pneumonia, and COVID-19  
354 mortality. These findings offer additional resources for primary care to prescribe  
355 improvements in lifestyle risk factors that can be used as a powerful ancillary measure  
356 against mortality from infectious disease.

357 To our knowledge, this is the first study to examine a comprehensive lifestyle risk factor  
358 index score incorporating multiple modifiable behaviours (physical activity, sedentary



359 behaviour, sleep quality, diet quality, alcohol consumption, and smoking status) in relation to  
360 infectious disease mortality risk. We were able to provide a comprehensive assessment for  
361 sleep quality that accounted for five sleep characteristics. We were, also, able to separate  
362 never drinkers from ex-drinkers who may have quit drinking due to prior alcohol-related  
363 problems. The dietary measure was comprehensive and included fruits, vegetables, grains,  
364 and red/processed meat. We also did not conflate the lifestyle behaviours with their  
365 outcomes, as some lifestyle behaviour indices have previously done by including weight  
366 status or other metabolic health indicators in the index (Bonaccio et al., 2019; Lee et al.,  
367 2011). We examined modifiable lifestyle behaviours in a large cohort with more than 10  
368 years follow-up for mortality, and the longest person-years follow-up in the field, and  
369 quantified the population health impact from different lifestyle behaviour combinations and  
370 synergistic interactions. The use of lifestyle behaviour indices such as ours based on current  
371 guidelines and best practice category thresholds for risk allows for policy-relevant lifestyle  
372 behaviours to be easily translated and assessed across settings and populations.

373 Opposing these strengths were several limitations. First, all lifestyle risk factors were  
374 measured with self-report questionnaires. Due to social desirability bias, misclassification is  
375 potentially non-random, and the results are most likely biased toward the null, with  
376 participants more likely to report desirable behaviours. Therefore, the preventable infectious  
377 disease mortality related to the healthy lifestyle indices is likely to be underestimated, as  
378 indicated by PF. **Second, the sleep quality scoring included sleep chronotype, which might be**  
379 **influenced more by genetic traits than behavioural factors** (Adan et al., 2012; Hur et al., 1998;  
380 Koskenvuo et al., 2007). Third, although the UK Biobank cohort is not representative of the  
381 general population (UK Biobank participants are healthier than the general population), prior  
382 epidemiological evidence has shown that there is little evidence for bias attributable to  
383 nonparticipation and exposure-disease relationships are widely generalizable (Fry et al.,

384 2017). This reinforces the epidemiological principle that associations are less dependent on  
385 the representativeness of the cohort, relative to prevalence (Galea et al., 2007).

#### 386 **4.1 Conclusions**

387 This large prospective cohort study examined the additive impact of healthy lifestyle  
388 behaviour combinations, which included the analysis of traditional and emerging lifestyle  
389 factors. We found that in middle aged and older adults, including those with cardiovascular  
390 disease and cancer, healthier lifestyle behaviours may protect against the most severe  
391 consequences of infectious disease. The findings based on public health guidelines and best  
392 practice recommendations provides information that clinicians and researchers can readily  
393 translate into practice and future research.

#### 394 **Declaration of competing interest**

395 The authors declare that they have no competing interests

#### 396 **Acknowledgements**

397 We are grateful to the UK Biobank participants. This research has been conducted using the  
398 UK Biobank Resource

## References

- Adan, A., Archer, S.N., Hidalgo, M.P., Di Milia, L., Natale, V., Randler, C., 2012. Circadian typology: A comprehensive review. *Chronobiol. Int.* 29, 1153–1175.  
<https://doi.org/10.3109/07420528.2012.719971>
- Allen, N., Sudlow, C., Downey, P., Peakman, T., Danesh, J., Elliott, P., Gallacher, J., Green, J., Matthews, P., Pell, J., Sprosen, T., Collins, R., 2012. UK Biobank: Current status and what it means for epidemiology. *Heal. Policy Technol.*  
<https://doi.org/10.1016/j.hlpt.2012.07.003>
- Almirall, J., Bolívar, I., Serra-Prat, M., Roig, J., Hospital, I., Carandell, E., Agustí, M., Ayuso, P., Estela, A., Torres, A., De Salas, J.M., Costa, J., Tristany, M., Grau, M.J., Sancho, S., Miguel, E., Fradera, M., Ochoa, I., Castany, M.J., Quilez, A., Marina, V., Subias, P., Jimeno, B., Bradnovich, A., Rodriguez, M., Ramon, E., Gardella, A., Ginés, C., Mestres, X., Armada, A., Mallafré, J., Roger, M., Gros, M.T., Les, N., Joanola, J., Doménech, J., Bundó, M., Trilla, M., Massons, J., Montero, J., Zurilla, E., Torán, P., Aizpurua, M.M., Lozano, G., Casals, J., Sorribes, J., Torrellas, D., Anglada, J.L.L., Salabarnada, J., Sanz, E., Gorgas, F., Ribas, A., Fau, E., Pellicer, I., Morales, S., Casas, A., Bernad, J., De Montoliu, A., Gaya, J., Vallés, R., Vazquez, A., Peiró, R., Aresté, G., Mengual, G.N., Viñes, M.C., Almerich, E., Lopez, M.A., Bel, J., Gosalves, A., Macip, S., Carrillo, E., Paulo, P., Pol, M., Sala, J., Mir, P., Carrera, P., Legazpi, I., Planellas, F., Beltran, A., Planas, T., Rovira, J., De Ciurana, M., Xargay, C., Cortés, R.B., Paredes, J., Olive, J.G., Montoya, P., Burcet, F.X., Alcantarilla, D., De Ribot, J., Gorgot, M.R., Bas, R.A., Rosa, M.B., Castells, J., Castillo, J.A., Torrent, J.C., Rodríguez, D., Rius, X., Navarro, M., Benet, J.M., Caballero, J.C., Llach, J., Sanglas, J., Morales, V., Solanella, J., Cardona, J.I., Ferrer, J., Solís, M.J., Güerri, F., Murillo, M.J., Llovet, M.D., Guinea,

I., Juáreztarrag, M.M., Alvarez, M., Bladé, J., Sánchez Oró, I., Martin, F., Cabré, J.J., Frigola, J., Boj, J., Chacon, A., Satué, E., Gallego, F., Montanyés, D., Basora, T., Martin, E., Gil, P., Roselló, M., Marimon, J., Costa, B., Gutiérrez, C., Moltó, E., Isach, A., Izzeddin, N., Campani, M., Ferré, J., Fernández, A., Jové, J., Vilalta, J., Ribera, E., Fernández, M., Ochoa, O., Vila Palacios, A., Donado-Mazarrón, A., Ramon, C., Caballol, R., Navarro, L., Masqué, J., Llor, L.L., Garcia, G., Arasa, M.J., Yoldi, A., Viloria, I., Vallespi, F., Clua, J.L.L., Basart, J.M., Ciurana, E., Monclus, J.F., Casanovas, A., Viñas, L., Checa, E., Marin, J., Santigosa, J., Arayo, F., Campillos, C., Juarez, A., Perez, J., Paredes, E., Rodriguez, J., Solà, Y., Pujol, J., Navarro, M.A., Casado, I., Madrid, M., Berdié, J., Andrés, M.J., Barragan, B., Torras, A., Gonzalez, S., Fuentes, A., El Hosn-Makarem, J.A., Pelaez, F., Ubieto, A., Fallada, A., Josa, A., Favà, E., Ros, M., Alonso, M., Pinazo, M.J., Borrás, S., Nolla, C., Bitrià, J., Araujo, O., Collado, A., Glaria, T., Montero, J.C., Flores, P., Serra, P., Torrellas, E., Buxadé, I., Mussoll, J., Gomez, M., Serrano, C., Pubill, M., Gost, J., Burdoy, E., Busquets, L.L., De Castro, S., Bartolomé, M., Corona, E., Valverde, R., Verde, Y., Alegre, M., Papiol, M., Martí, O., Catalá, M., Martinez, M.A., Diaz, E., Borrás, A., Aznar, F., Riera, F., Colom, I., Calvet, E., Nicolás, J., Ruiz, J., Mateu, C., Arranz, J., Fé, A., Puig, B., Gutiérrez, M., Morant, L.L., Llull, M., Estelrich, J., Quintana, L., Llabrés, C., Sureda, M.M., Cuevas, L., Muñoz, Y., Llobera, J., Iñiguez, M., Guasch, J., Sánchez, F., Pascual, J., Castelló, A., Gómez, L.L., Marin, P., Garcia, C., Moreno, P., Coll, M., Palma, C., Ribera, C., Aldosa, J., Alonso, C., Bergés, A., Burgués, J., Burgués, L.L., Busquets, J., Casal, D., Cerdán, N., Crespo, X., Duat, R., Escoda, J., Fiter, M., Font, A., Fraysse, M., Fuentes, S., García-Núñez, R., López-Pinacho, T., Masardo, M., Martínez-Illescas, J., Morisset, P., Pallarés, M., Pérez-Serra, R., Plà, A., Pons, E., Ruiz, A., Rodríguez-Picart, J.C., Sánchez-Claver, J., Sylvestre, E., Tolosa, R., Touceda, J.A., Varela, J.R., Vidal, J.C., 2008. New evidence

- of risk factors for community-acquired pneumonia: A population-based study. *Eur. Respir. J.* 31, 1274–1284. <https://doi.org/10.1183/09031936.00095807>
- Ambrus, J.L., Ambrus, J.L., 2004. Nutrition and infectious diseases in developing countries and problems of acquired immunodeficiency syndrome. *Exp. Biol. Med.* 229, 464–472. <https://doi.org/10.1177/153537020422900603>
- Andersson, T., Alfredsson, L., Källberg, H., Zdravkovic, S., Ahlbom, A., 2005. Calculating measures of biological interaction. *Eur. J. Epidemiol.* 20, 575–579. <https://doi.org/10.1007/s10654-005-7835-x>
- Baik, I., Curhan, G.C., Rimm, E.B., Bendich, A., Willett, W.C., Fawzi, W.W., 2000. A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. *Arch. Intern. Med.* 160, 3082–3088. <https://doi.org/10.1001/archinte.160.20.3082>
- Bonaccio, M., Di Castelnuovo, A., Costanzo, S., De Curtis, A., Persichillo, M., Cerletti, C., Donati, M.B., de Gaetano, G., Iacoviello, L., Investigators, M.S., 2019. Impact of combined healthy lifestyle factors on survival in an adult general population and in high-risk groups: prospective results from the Moli-sani study. *J. Intern. Med.* 286, 207–220. <https://doi.org/10.1111/joim.12637>
- Bull, F., Saad Al-Ansari, S., Biddle, S., Borodulin, K., Buman, M., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., Dempsey, P., DiPietro, L., Ekelund, U., Firth, J., Friedenreich, C., Garcia, L., Gichu, M., Jago, R., Katzmarzyk, P., Lambert, E., Leitzmann, M., Milton, K., Ortega, F., Ranasinghe, C., Stamatakis, E., Willumsen, J., 2020. World Health Organization 2020 Guidelines on Physical Activity and Sedentary Behaviour. *Br. J. Sports Med.* 1451–1462. <https://doi.org/10.1136/bjsports-2020-102955>
- Buuren, S. van, Groothuis-Oudshoorn, K., 2010. mice: Multivariate imputation by chained

equations in R. *J. Stat. Softw.* 1–68. <https://doi.org/10.1080/10580530.2013.739883>

Carter, B.D., Abnet, C.C., Feskanich, D., Freedman, N.D., Hartge, P., Lewis, C.E., Ockene, J.K., Prentice, R.L., Speizer, F.E., Thun, M.J., Jacobs, E.J., 2015. Smoking and Mortality — Beyond Established Causes. *N. Engl. J. Med.* 372, 631–640. <https://doi.org/10.1056/nejmsa1407211>

Cassini, A., Högberg, L.D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G.S., Colomb-Cotinat, M., Kretzschmar, M.E., Devleeschauwer, B., Cecchini, M., Ouakrim, D.A., Oliveira, T.C., Struelens, M.J., Suetens, C., Monnet, D.L., Strauss, R., Mertens, K., Struyf, T., Catry, B., Latour, K., Ivanov, I.N., Dobрева, E.G., Tambic Andrašević, A., Soprek, S., Budimir, A., Paphitou, N., Žemlicková, H., Schytte Olsen, S., Wolff Sönksen, U., Martin, P., Ivanova, M., Lyytikäinen, O., Jalava, J., Coignard, B., Eckmanns, T., Abu Sin, M., Haller, S., Daikos, G.L., Gikas, A., Tsiodras, S., Kontopidou, F., Tóth, Á., Hajdu, Á., Guólaugsson, Ó., Kristinsson, K.G., Murchan, S., Burns, K., Pezzotti, P., Gagliotti, C., Dumpis, U., Liuimiene, A., Perrin, M., Borg, M.A., de Greeff, S.C., Monen, J.C., Koek, M.B., Elstrøm, P., Zabicka, D., Deptula, A., Hryniewicz, W., Caniça, M., Nogueira, P.J., Fernandes, P.A., Manageiro, V., Popescu, G.A., Serban, R.I., Schréterová, E., Litvová, S., Štefkovicová, M., Kolman, J., Klavs, I., Korošec, A., Aracil, B., Asensio, A., Pérez-Vázquez, M., Billström, H., Larsson, S., Reilly, J.S., Johnson, A., Hopkins, S., 2019. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. *Lancet Infect. Dis.* 19, 56–66. [https://doi.org/10.1016/S1473-3099\(18\)30605-4](https://doi.org/10.1016/S1473-3099(18)30605-4)

Chau, J.Y., Grunseit, A., Midthjell, K., Holmen, J., Holmen, T.L., Bauman, A.E., Van Der Ploeg, H.P., 2015. Sedentary behaviour and risk of mortality from all-causes and

- cardiometabolic diseases in adults: Evidence from the HUNT3 population cohort. *Br. J. Sports Med.* 49, 737–742. <https://doi.org/10.1136/bjsports-2012-091974>
- Chau, J.Y., Grunseit, A.C., Chey, T., Stamatakis, E., Brown, W.J., Matthews, C.E., Bauman, A.E., Van Der Ploeg, H.P., 2013. Daily sitting time and all-cause mortality: A meta-analysis. *PLoS One* 8, 1–14. <https://doi.org/10.1371/journal.pone.0080000>
- Chiuve, S.E., Fung, T.T., Rimm, E.B., Hu, F.B., McCullough, M.L., Wang, M., Stampfer, M.J., Willett, W.C., 2012. Alternative dietary indices both strongly predict risk of chronic disease. *J. Nutr.* 142, 1009–1018. <https://doi.org/10.3945/jn.111.157222>
- Craig, C.L., Marshall, A.L., Sjöström, M., Bauman, A.E., Booth, M.L., Ainsworth, B.E., Pratt, M., Ekelund, U., Yngve, A., Sallis, J.F., Oja, P., 2003. International physical activity questionnaire: 12-Country reliability and validity. *Med. Sci. Sports Exerc.* 35, 1381–1395. <https://doi.org/10.1249/01.MSS.0000078924.61453.FB>
- Ding, D., Rogers, K., van der Ploeg, H., Stamatakis, E., Bauman, A.E., 2015. Traditional and Emerging Lifestyle Risk Behaviors and All-Cause Mortality in Middle-Aged and Older Adults: Evidence from a Large Population-Based Australian Cohort. *PLoS Med.* 12, 1–21. <https://doi.org/10.1371/journal.pmed.1001917>
- Dunstan, D.W., Howard, B., Healy, G.N., Owen, N., 2012. Too much sitting - A health hazard. *Diabetes Res. Clin. Pract.* 97, 368–376. <https://doi.org/10.1016/j.diabres.2012.05.020>
- Fan, M., Sun, D., Zhou, T., Heianza, Y., Lv, J., Li, L., Qi, L., 2020. Sleep patterns, genetic susceptibility, and incident cardiovascular disease: A prospective study of 385 292 UK biobank participants. *Eur. Heart J.* 41, 1182–1189. <https://doi.org/10.1093/eurheartj/ehz849>

- Ferkol, T., Schraufnagel, D., 2014. The global burden of respiratory disease. *Ann. Am. Thorac. Soc.* 11, 404–406. <https://doi.org/10.1513/AnnalsATS.201311-405PS>
- Fletcher, G.F., Landolfo, C., Niebauer, J., Ozemek, C., Arena, R., Lavie, C.J., 2018. Promoting Physical Activity and Exercise: JACC Health Promotion Series. *J. Am. Coll. Cardiol.* 72, 1622–1639. <https://doi.org/10.1016/j.jacc.2018.08.2141>
- Friedman, G.D., Klatsky, A.L., 1993. Is alcohol good for your health? *N. Engl. J. Med.* 1882–1883.
- Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., Allen, N.E., 2017. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am. J. Epidemiol.* 186, 1026–1034. <https://doi.org/10.1093/aje/kwx246>
- Galea, S., Ph, D.R., Tracy, M., 2007. Participation Rates in Epidemiologic Studies. *Ann. Epidemiol.* 17, 643–653. <https://doi.org/10.1016/j.annepidem.2007.03.013>
- Gelband, H., Miller-Petrie, M., Pant, S., Gandra, S., Levinson, J., Barter, D., White, A., Laxminarayan, R., 2015. The state of the world’s antibiotics 2015. *Wound Heal. South. Africa* 8, 30–34.
- Gordon, J.E., 1968. Weanling diarrhoea—a synergism of infection and nutrition, in: *Interactions of Malnutrition and Infection.* p. 216.
- Hamer, M., Kivimäki, M., Gale, C.R., Batty, G.D., 2020. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK. *Brain. Behav. Immun.* 87, 184–187. <https://doi.org/10.1016/j.bbi.2020.05.059>
- Hamer, M., O’Donovan, G., Stamatakis, E., 2019. Lifestyle risk factors, obesity and



infectious disease mortality in the general population: Linkage study of 97,844 adults from England and Scotland. *Prev. Med. (Baltim)*. 123, 65–70.

<https://doi.org/10.1016/j.ypmed.2019.03.002>

Hamer, M., Stamatakis, E., Steptoe, A., 2014. Effects of substituting sedentary time with physical activity on metabolic risk. *Med. Sci. Sports Exerc.* 46, 1946–1950.

<https://doi.org/10.1249/MSS.0000000000000317>

Hamilton, M., Hamilton, D., Zderic, T., 2007. Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. *Diabetes* 56, 2655–2667. <https://doi.org/10.2337/db07-0882.CVD>

Health, D. of, 2016. Alcohol guidelines review—Report from the Guidelines development group to the UK Chief Medical Officers.

Hersey, P., Prendergast, D., Edwards, A., 1983. Effects of cigarette smoking on the immune system Follow-up studies in normal subjects after cessation of smoking. *Med. J. Aust.* 2, 425–429. <https://doi.org/10.5694/j.1326-5377.1983.tb122565.x>

Hur, Y.-M., Bourchar Jr, T., Lykken, D., 1998. Genetic and environmental influence on morningness-eveningness. *Pers. Individ. Dif.* 25, 917–925.

Huttunen, R., Heikkinen, T., Syrjänen, J., 2011. Smoking and the outcome of infection. *J. Intern. Med.* 269, 258–269. <https://doi.org/10.1111/j.1365-2796.2010.02332.x>

Ibarra-Coronado, E.G., Pantaleón-Martínez, A.M., Velazquez-Moctezuma, J., Prospéro-García, O., Méndez-Díaz, M., Pérez-Tapia, M., Pavón, L., Morales-Montor, J., 2015. The Bidirectional Relationship between Sleep and Immunity against Infections. *J. Immunol. Res.* 2015. <https://doi.org/10.1155/2015/678164>

Inoue, Y., Koizumi, A., Wada, Y., Iso, H., Watanabe, Y., Date, C., Yamamoto, A., Kikuchi,

- S., Inaba, Y., Toyoshima, H., Tamakoshi, A., 2007. Risk and protective factors related to mortality from pneumonia among middle-aged and elderly community residents: The JACC study. *J. Epidemiol.* 17, 194–202. <https://doi.org/10.2188/jea.17.194>
- Irwin, M.R., 2015. Why sleep is important for health: A psychoneuroimmunology perspective. *Annu. Rev. Psychol.* 66, 143–172. <https://doi.org/10.1146/annurev-psych-010213-115205>
- Kadri, S.S., 2020. Key Takeaways from the U.S. CDC’s 2019 Antibiotic Resistance Threats Report for Frontline Providers. *Crit. Care Med.* 939–945. <https://doi.org/10.1097/CCM.0000000000004371>
- Källberg, H., Ahlbom, A., Alfredsson, L., 2006. Calculating measures of biological interaction using R. *Eur. J. Epidemiol.* 21, 571–573. <https://doi.org/10.1007/s10654-006-9037-6>
- Katona, P., Katona-Apte, J., 2008. The interaction between nutrition and infection. *Clin. Infect. Dis.* 46, 1582–1588. <https://doi.org/10.1086/587658>
- Knott, C.S., Coombs, N., Stamatakis, E., Biddulph, J.P., 2015. All cause mortality and the case for age specific alcohol consumption guidelines: Pooled analyses of up to 10 population based cohorts. *BMJ* 350. <https://doi.org/10.1136/bmj.h384>
- Koskenvuo, M., Hublin, C., Partinen, M., Heikkilä, K., Kaprio, J., 2007. Heritability of diurnal type: A nationwide study of 8753 adult twin pairs. *J. Sleep Res.* 16, 156–162. <https://doi.org/10.1111/j.1365-2869.2007.00580.x>
- Lee, C., Sui, X., Hooker, S.P., Ebert, J.R.H., Blair, S.N., 2011. Combined Impact of Lifestyle Factors on Cancer Mortality in Men. <https://doi.org/10.1016/j.annepidem.2011.04.010>
- Mackinnon, L.T., 1999. Advances in exercise immunology. *Human Kinetics.*

Marston, H.D., Dixon, D.M., Knisely, J.M., Palmore, T.N., Fauci, A.S., 2016. Antimicrobial resistance. *JAMA - J. Am. Med. Assoc.* 316, 1193–1204.

<https://doi.org/10.1001/jama.2016.11764>

Matthews, C.E., Ockene, I.R.A.S., Freedson, P.S., Rosal, M.C., Merriam, P.A., Hebert, J.R., 2002. Moderate to vigorous physical activity and risk of upper-respiratory tract infection. *Med. Sci. Sport. Exerc.* 34, 1242–1248.

McCullough, M.L., Feskanich, D., Stampfer, M.J., Giovannucci, E.L., Rimm, E.B., Hu, F.B., Spiegelman, D., Hunter, D.J., Colditz, G.A., Willett, W.C., 2002. Diet quality and major chronic disease risk in men and women: Moving toward improved dietary guidance.

*Am. J. Clin. Nutr.* 76, 1261–1271. <https://doi.org/10.1093/ajcn/76.6.1261>

Nair, H., Brooks, W.A., Katz, M., Roca, A., Berkley, J.A., Madhi, S.A., Simmerman, J.M., Gordon, A., Sato, M., Howie, S., Krishnan, A., Ope, M., Lindblade, K.A., Carosone-Link, P., Lucero, M., Ochieng, W., Kamimoto, L., Dueger, E., Bhat, N., Vong, S., Theodoratou, E., Chittaganpitch, M., Chimah, O., Balmaseda, A., Buchy, P., Harris, E., Evans, V., Katayose, M., Gaur, B., O’Callaghan-Gordo, C., Goswami, D., Arvelo, W., Venter, M., Briese, T., Tokarz, R., Widdowson, M.A., Mounts, A.W., Breiman, R.F., Feikin, D.R., Klugman, K.P., Olsen, S.J., Gessner, B.D., Wright, P.F., Rudan, I., Broor, S., Simões, E.A., Campbell, H., 2011. Global burden of respiratory infections due to seasonal influenza in young children: A systematic review and meta-analysis. *Lancet* 378, 1917–1930. [https://doi.org/10.1016/S0140-6736\(11\)61051-9](https://doi.org/10.1016/S0140-6736(11)61051-9)

Nieman, D.C., 1994. Exercise, Infection, and Immunity. *Int. J. Sports Med.* 15, S131–S141. <https://doi.org/10.1055/s-2007-1021128>

Nieman, D.C., Henson, D.A., Austin, M.D., Sha, W., 2011. Upper respiratory tract infection is reduced in physically fit and active adults. *Br. J. Sports Med.* 45, 987–992.

<https://doi.org/10.1136/bjism.2010.077875>

- Nieman, D.C., Nehlsen-Cannarella, S.L., Markoff, P.A., Balk-Lamberton, A.J., Yang, H., Chritton, D.B.W., Lee, J.W., Arabatzis, K., 1990. The effects of moderate exercise training on natural killer cells and acute upper respiratory tract infections. *Int. J. Sports Med.* 11, 467–473. <https://doi.org/10.1055/s-2007-1024839>
- Opp, M.R., Krueger, J.M., 2015. Sleep and immunity: A growing field with clinical impact. *Brain. Behav. Immun.* 47, 1–3. <https://doi.org/10.1016/j.bbi.2015.03.011>
- Paulsen, J., Mehl, A., Dewan, A., Solliga, E., Dama, J.K., Asvold, B., 2017. Associations of obesity and lifestyle with the risk and mortality of bloodstream infection in a general population : a 15-year follow-up of 64 027 individuals in the HUNT Study. *Int. J. Epidemiol.* 46, 1573–1581. <https://doi.org/10.1093/ije/dyx091>
- Perreault, K., Bauman, A., Johnson, N., Britton, A., Rangul, V., Stamatakis, E., 2017. Does physical activity moderate the association between alcohol drinking and all-cause, cancer and cardiovascular diseases mortality? A pooled analysis of eight British population cohorts. *Br. J. Sports Med.* 51, 651–657. <https://doi.org/10.1136/bjsports-2016-096194>
- Prather, A.A., Leung, C.W., 2016. Association of insufficient sleep with respiratory infection among adults in the United States. *JAMA Intern. Med.* 176, 850–852. <https://doi.org/10.1001/jamainternmed.2016.0787>
- Rehm, J., Baliunas, D., Borges, G.L.G., Graham, K., Irving, H., Kehoe, T., Parry, C.D., Patra, J., Popova, S., Poznyak, V., Roerecke, M., Room, R., Samokhvalov, A. V., Taylor, B., 2010. The relation between different dimensions of alcohol consumption and burden of disease: An overview. *Addiction* 105, 817–843. <https://doi.org/10.1111/j.1360-0443.2010.02899.x>

- Rosenberg, G., Bauld, L., Hooper, L., Buykx, P., Holmes, J., Vohra, J., 2018. New national alcohol guidelines in the UK: Public awareness, understanding and behavioural intentions. *J. Public Heal. (United Kingdom)* 40, 549–556.  
<https://doi.org/10.1093/pubmed/fox126>
- Rudd, K.E., Johnson, S.C., Agesa, K.M., Shackelford, K.A., Tsoi, D., Kievlan, D.R., Colombara, D. V., Ikuta, K.S., Kissoon, N., Finfer, S., Fleischmann-Struzek, C., Machado, F.R., Reinhart, K.K., Rowan, K., Seymour, C.W., Watson, R.S., West, T.E., Marinho, F., Hay, S.I., Lozano, R., Lopez, A.D., Angus, D.C., Murray, C.J.L., Naghavi, M., 2020. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *Lancet* 395, 200–211.  
[https://doi.org/10.1016/S0140-6736\(19\)32989-7](https://doi.org/10.1016/S0140-6736(19)32989-7)
- Sallis, J.F., Adlakha, D., Oyeyemi, A., Salvo, D., 2020. An international physical activity and public health research agenda to inform coronavirus disease-2019 policies and practices. *J. Sport Heal. Sci.* 9, 328–334. <https://doi.org/10.1016/j.jshs.2020.05.005>
- Samokhvalov, A. V., Irving, H.M., Rehm, J., 2010. Alcohol consumption as a risk factor for pneumonia: A systematic review and meta-analysis. *Epidemiol. Infect.* 138, 1789–1795.  
<https://doi.org/10.1017/S0950268810000774>
- Scrimshaw, N.S., SanGiovanni, J.P., 1997. Synergism of nutrition, infection, and immunity: An overview. *Am. J. Clin. Nutr.* 66. <https://doi.org/10.1093/ajcn/66.2.464S>
- Song, J.H., Thamlikitkul, V., Hsueh, P.R., 2011. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. *Int. J. Antimicrob. Agents* 38, 108–117. <https://doi.org/10.1016/j.ijantimicag.2011.02.017>
- Sopori, M., 2002. Effects of cigarette smoke on the immune system. *Nat. Rev. Immunol.* 2, 372–377.

- Stamatakis, E., Rogers, K., Ding, D., Berrigan, D., Chau, J., Hamer, M., Bauman, A., 2015. All-cause mortality effects of replacing sedentary time with physical activity and sleeping using an isothermal substitution model: A prospective study of 201,129 mid-aged and older adults. *Int. J. Behav. Nutr. Phys. Act.* 12. <https://doi.org/10.1186/s12966-015-0280-7>
- Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T., Peakman, T., Collins, R., 2015. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med.* 12, 1–10. <https://doi.org/10.1371/journal.pmed.1001779>
- Tacconelli, E., Sifakis, F., Harbarth, S., Schrijver, R., van Mourik, M., Voss, A., Sharland, M., Rajendran, N.B., Rodríguez-Baño, J., Bielicki, J., de Kraker, M., Gandra, S., Gastmeier, P., Gilchrist, K., Gikas, A., Gladstone, B.P., Goossens, H., Jafri, H., Kahlmeter, G., Leus, F., Luxemburger, C., Malhotra-Kumar, S., Marasca, G., McCarthy, M., Navarro, M.D., Nuñez-Nuñez, M., Oualim, A., Price, J., Robert, J., Sommer, H., von Cube, M., Vuong, C., Wiegand, I., Witschi, A.T., Wolkewitz, M., 2018. Surveillance for control of antimicrobial resistance. *Lancet Infect. Dis.* 18, e99–e106. [https://doi.org/10.1016/S1473-3099\(17\)30485-1](https://doi.org/10.1016/S1473-3099(17)30485-1)
- Townsend, P., Phillimore, P., Beattie, A., 1988. *Health and deprivation: inequality and the North.* Routledge.
- UK Biobank, 2007. UK Biobank: Protocol for a large-scale prospective epidemiological resource. UKBB-PROT-09-06 (Main Phase).
- Wang, H.E., Baddley, J., Griffin, R.L., Judd, S., Howard, G., Donnelly, J.P., Safford, M.M., 2014. Physical inactivity and long-term rates of community-acquired sepsis. *Prev. Med.*

(Baltim). 65, 58–64. <https://doi.org/10.1016/j.ypmed.2014.04.017>

Wang, S., Liu, X., Chen, Q., Liu, C., Huang, C., Fang, X., 2017. The role of increased body mass index in outcomes of sepsis: A systematic review and meta-analysis. *BMC Anesthesiol.* 17, 1–11. <https://doi.org/10.1186/s12871-017-0405-4>

Welte, T., Torres, A., Nathwani, D., 2012. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 67, 71–79. <https://doi.org/10.1136/thx.2009.129502>

Weycker, D., Strutton, D., Edelsberg, J., Sato, R., Jackson, L.A., 2010. Clinical and economic burden of pneumococcal disease in older US adults. *Vaccine* 28, 4955–4960. <https://doi.org/10.1016/j.vaccine.2010.05.030>

Xiao, Q., Keadle, S.K., Hollenbeck, A.R., Matthews, C.E., 2014. Sleep duration and total and cause-specific mortality in a large US cohort: Interrelationships with physical activity, sedentary behavior, and body mass index. *Am. J. Epidemiol.* 180, 997–1006. <https://doi.org/10.1093/aje/kwu222>

Table 1: Lifestyle risk factor categories and index score

<b>Risk factor</b>	<b>Category</b>	<b>Definition</b>	<b>Index score</b>
Physical Activity	Inactive	0 min	0
	Insufficient	1-149 min	1
	Sufficient	≥ 150 min	2
Sedentary Behaviour	High SB	> 7 hrs	0
	Mod SB	4-7 hrs	1
	Low SB	< 4 hrs	2
Sleep	Poor index	≤ 1 sleep score	0
	Moderate index	2-3 sleep score	1
	Good index	> 3 sleep score	2
Diet	Poor quality	0 diet score	0
	Moderate quality	1 diet score	1
	Good quality	2 diet score	2
*Alcohol	Ex-drinker	*	0
	Above guideline	*	1
	Never drinker	*	2
	Within guideline	*	2
Smoking	Current		0
	Previous		1
	Never		2

\*In the United Kingdom, 1 unit = 8g of alcohol; Heavy drinker ≥14 units; To derive a combined lifestyle behaviour index score, ex-drinker and never drinkers were combined into the same category



Table 2: Study population characteristics at baseline. Values are means (SD) unless stated otherwise

Characteristic	Lifestyle Behaviour Index Score						
	0-4	6	7	8	9	10	10-12
Sample size (n)	29,281	33,641	54,524	75,083	84,975	80,357	110,582
Follow-up duration (years)	10.7 (2.0)	10.9 (1.8)	11.0 (1.6)	11.0 (1.5)	11.0 (1.4)	11.1 (1.4)	11.1 (1.3)
Age (years)	55.7 (8.0)	56.3 (7.9)	56.5 (8.0)	56.6 (8.0)	56.5 (8.1)	56.5 (8.1)	56.6 (8.3)
Women (%)	33.9	38.1	42.3	47.8	54.2	61.8	71.0
Physical activity, n (%)							
Inactive	18,355 (62.7)	14,267 (42.4)	17,485 (32.1)	18,280 (24.3)	15,400 (18.1)	8,859 (11.0)	2,575 (2.3)
Insufficient	7935 (27.1)	11,830 (35.2)	19,565 (35.9)	25,525 (34.0)	27,763 (32.7)	25,445 (31.7)	22,546 (20.4)
Sufficient	2991 (10.2)	7,544 (22.4)	17,474 (32.0)	31,278 (41.7)	41,812 (49.2)	46,053 (57.3)	85,461 (77.3)
Sedentary							
High	12,280 (41.9)	9,328 (27.7)	10,976 (20.1)	10,513 (14.0)	7,917 (9.3)	4,778 (5.9)	1,693 (1.5)
Mod	14,857 (50.7)	19,861 (59.0)	33,738 (61.9)	46,350 (61.7)	50,083 (58.9)	43,161 (53.7)	41,879 (37.9)
Low	2,144 (7.3)	4,452 (13.2)	9,810 (18.0)	18,220 (24.3)	26,975 (31.7)	32,418 (40.3)	67,010 (60.6)
Sleep							
Poor quality (0-1)	4,223 (14.4)	2,618 (7.8)	2,702 (5.0)	2,319 (3.1)	1,614 (1.9)	831 (1.0)	213 (0.2)
Moderate quality (2-3)	19,984 (68.2)	21,595 (64.2)	32,430 (59.5)	39,146 (52.1)	37,002 (43.5)	28,627 (35.6)	22,351 (20.2)
Good quality (4-5)	5,074 (17.3)	9,428 (28.0)	19,392 (35.6)	33,618 (44.8)	46,359 (54.6)	50,899 (63.3)	88,018 (79.6)
Diet							
Poor quality	15,755 (53.8)	11,986 (35.6)	14,254 (26.1)	13,914 (18.5)	10,843 (12.8)	6,407 (8.0)	2,105 (1.9)
Moderate quality	11,110 (37.9)	15,717 (46.7)	26,137 (47.9)	34,933 (46.5)	36,892 (43.4)	32,400 (40.3)	29,704 (26.9)
Good quality	2,416 (8.3)	5,938 (17.7)	14,133 (25.9)	26,236 (34.9)	37,240 (43.8)	41,550 (51.7)	78,773 (71.2)
Alcohol*							
Ex-drinker	5,378 (18.4)	3,074 (9.1)	3,318 (6.1)	2,761 (3.7)	1,432 (1.7)	395 (0.5)	0 (0)
Above guideline	20,170 (68.9)	22,511 (66.9)	33,212 (60.9)	38,912 (51.8)	32,824 (38.6)	17,903 (22.3)	4,450 (4.0)
Non-drinker	662 (2.3)	1,116 (3.3)	2,251 (4.1)	3,565 (4.7)	4,390 (5.2)	3,981 (5.0)	3,625 (3.3)
Within guideline	3,071 (10.5)	6,940 (20.6)	15,743 (28.9)	29,845 (39.7)	46,329 (54.5)	58,078 (72.3)	102,507 (92.7)
Smoking							
Current	13,416 (45.8)	9,168 (27.3)	9,691 (17.8)	8,091 (10.8)	5,057 (6.0)	2,466 (3.1)	692 (0.6)
Previous	12,131 (41.4)	16,390 (48.7)	26,429 (48.5)	33,555 (44.7)	32,164 (37.9)	23,784 (29.6)	18,537 (16.8)

Never	3,734 (12.8)	8,083 (24.0)	18,404 (33.8)	33,437 (44.5)	47,754 (56.2)	54,107 (67.3)	91,353 (82.6)
Townsend deprivation index [median (IQR)]	-0.9 (-3.0, 2.4)	-1.7 (-3.4, 1.3)	-2.0 (-3.5, 0.9)	-2.1 (-3.6, 0.5)	-2.3 (-3.7, 0.2)	-2.4 (-3.7, 0.0)	-2.5 (-3.8, -0.3)
Body Mass Index	28.8 (5.3)	28.6 (5.1)	28.2 (4.9)	27.9 (4.8)	27.5 (4.7)	27.0 (4.6)	26.1 (4.3)
Ethnicity (%)							
White	95.8	95.9	95.5	95.2	94.8	94.5	94.9
South Asian	1.3	1.4	1.6	1.8	2.0	2.0	1.7
Black	1.3	1.2	1.4	1.4	1.4	1.6	1.6
Chinese	0.1	0.2	0.2	0.3	0.3	0.4	0.4
Other	1.5	1.4	1.3	1.3	1.4	1.5	1.4
Comorbidities (%)							
Cancer	8.2	7.9	8.3	8.1	8.3	8.4	8.5
Cardiovascular disease	38.3	35.8	33.9	31.4	29.0	27.0	23.7
Diabetes	8.0	7.0	6.1	5.4	4.8	4.1	3.1
Chronic respiratory illness	16.4	14.6	13.6	13.2	12.6	12.2	11.3
Liver disease	0.6	0.4	0.3	0.3	0.2	0.2	0.2
End-stage renal disease	0.2	0.1	0.1	0.1	<0.1	<0.1	<0.1
Immune disorders/HIV	0.5	0.4	0.4	0.4	0.4	0.3	0.3

\* In the United Kingdom, 1 unit = 8g of alcohol; Heavy drinker  $\geq 14$  units; Physical activity was classified based on MET-min/week where inactive = 0 MET-min/week, insufficient < 600 MET-min/week (<150 min of mvpa), sufficient  $\geq 600$  MET-min/week ( $\geq 150$  min of mvpa); Sedentary was classified as High >7 hrs, Mod  $\geq 4$  hrs, Low <4 hrs; Sleep quality was based on five sleep characteristics which included: morning chronotype, sleep duration, insomnia, snoring, and daytime sleepiness; Diet was based on the Alternative Healthy Eating Index; Townsend deprivation index scores ranged from -6 to 11. Scores were derived from national census data. Each participant was assigned a score relative to the output area in which their postcode was located. Higher scores reflect a higher degree of socioeconomic deprivation; Body mass index = weight (kg) / height (m<sup>2</sup>)

Table 3: Lifestyle risk factors and infectious disease mortality hazard ratio

Risk factor		N	Events	Model 1		Model 2	
				HR (95% CI)		HR (95% CI)	
Physical Activity							
	Inactive	95,221	1288	1.00	(ref)	1.00	(ref)
	Insufficient	140,609	1173	0.65	(0.60, 0.70)	0.77	(0.71, 0.83)
	Sufficient	232,613	1715	0.52	(0.48, 0.56)	0.64	(0.59, 0.69)
Sedentary Behaviour							
	High	57,485	748	1.00	(ref)	1.00	(ref)
	Moderate	249,929	2354	0.70	(0.65, 0.76)	0.86	(0.79, 0.93)
	Low	161,029	1074	0.60	(0.55, 0.66)	0.79	(0.72, 0.87)
Sleep							
	Poor	14,520	212	1.00	(ref)	1.00	(ref)
	Moderate	201,135	2004	0.66	(0.57, 0.76)	0.83	(0.72, 0.97)
	Good	252,788	1960	0.54	(0.47, 0.62)	0.80	(0.70, 0.92)
Diet							
	Poor	75,264	750	1.00	(ref)	1.00	(ref)
	Moderate	186,893	1668	0.82	(0.75, 0.89)	0.94	(0.87, 1.03)
	Good	206,286	1758	0.67	(0.62, 0.73)	0.85	(0.77, 0.93)
Alcohol							
	Ex-drinker	16,257	340	1.00	(ref)	1.00	(ref)
	Above guideline	169,542	1584	0.39	(0.35, 0.44)	0.53	(0.47, 0.60)
	Never drinker	19,522	211	0.55	(0.46, 0.65)	0.76	(0.64, 0.91)
	Within guideline	261,842	2041	0.40	(0.35, 0.45)	0.56	(0.50, 0.63)
Smoking							
	Current	48,581	905	1.00	(ref)	1.00	(ref)
	Previous	162,990	1814	0.42	(0.39, 0.45)	0.50	(0.46, 0.54)
	Never	256,872	1457	0.28	(0.26, 0.30)	0.37	(0.34, 0.41)

Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, socioeconomic status, ethnicity, BMI, cardiovascular disease, cancer, diabetes, hypertension, use of anti-hypertensive medication, use of corticosteroids, chronic lung/respiratory disease, liver diseases, diabetes, end-stage renal disease, and immune disorders/HIV and mutually adjusted for each lifestyle risk factor; Physical Activity = [Inactive = 0 min of moderate to vigorous physical activity (mvpa)]; Insufficient = 1-149 min of mvpa; Sufficient  $\geq$  150 min of mvpa; Sedentary Behaviour = [High > 7 hrs; Moderate = 4-7 hrs; Low <4 hrs]; Sleep = [Poor index  $\leq$  1 sleep score; Moderate index 2-3 sleep score; Good index > 3 sleep score]; Diet = [Poor quality = 0 diet score; Moderate quality = 1 diet score; Good quality = 2 diet score]. Alcohol = [Above guideline  $\geq$ 14 units; 1 unit = 8 g of alcohol].

Table 4: Lifestyle risk factors and pneumonia mortality hazard ratio

Risk factor		N	Events	Model 1		Model 2	
				HR (95% CI)		HR (95% CI)	
Physical Activity							
	Inactive	95,221	984	1.00	(ref)	1.00	(ref)
	Insufficient	140,609	893	0.64	(0.59, 0.71)	0.77	(0.70, 0.84)
	Sufficient	232,613	1293	0.51	(0.47, 0.55)	0.63	(0.58, 0.69)
Sedentary Behaviour							
	High	57,485	583	1.00	(ref)	1.00	(ref)
	Moderate	249,929	1773	0.68	(0.62, 0.75)	0.83	(0.76, 0.92)
	Low	161,029	814	0.60	(0.53, 0.66)	0.78	(0.70, 0.87)
Sleep							
	Poor	14,520	160	1.00	(ref)	1.00	(ref)
	Moderate	201,135	1521	0.66	(0.56, 0.78)	0.83	(0.70, 0.98)
	Good	252,788	1489	0.54	(0.46, 0.63)	0.80	(0.68, 0.95)
Diet							
	Poor	75,264	584	1.00	(ref)	1.00	(ref)
	Moderate	186,893	1278	0.80	(0.73, 0.88)	0.94	(0.85, 1.03)
	Good	206,286	1308	0.64	(0.58, 0.70)	0.82	(0.75, 0.91)
Alcohol							
	Ex-drinker	16,257	261	1.00	(ref)	1.00	(ref)
	Above guideline	169,542	1240	0.39	(0.34, 0.45)	0.54	(0.47, 0.61)
	Never drinker	19,522	156	0.53	(0.43, 0.65)	0.75	(0.61, 0.92)
	Within guideline	261,842	1513	0.38	(0.34, 0.44)	0.55	(0.48, 0.63)
Smoking							
	Current	48,581	727	1.00	(ref)	1.00	(ref)
	Previous	162,990	1393	0.39	(0.36, 0.43)	0.46	(0.42, 0.51)
	Never	256,872	1050	0.25	(0.23, 0.28)	0.33	(0.30, 0.36)

Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, socioeconomic status, ethnicity, BMI, cardiovascular disease, cancer, diabetes, hypertension, use of anti-hypertensive medication, use of corticosteroids, chronic lung/respiratory disease, liver diseases, diabetes, end-stage renal disease, and immune disorders/HIV and mutually adjusted for each lifestyle risk factor; Physical Activity = [Inactive = 0 min of moderate to vigorous physical activity (mvpa)]; Insufficient = 1-149 min of mvpa; Sufficient  $\geq$  150 min of mvpa; Sedentary Behaviour = [High > 7 hrs; Moderate = 4-7 hrs; Low <4 hrs]; Sleep = [Poor index  $\leq$  1 sleep score; Moderate index 2-3 sleep score; Good index > 3 sleep score]; Diet = [Poor quality = 0 diet score; Moderate quality = 1 diet score; Good quality = 2 diet score]. Alcohol = [Above guideline  $\geq$ 14 units; 1 unit = 8 g of alcohol].

Table 5: Lifestyle risk factors and COVID-19 mortality risk ratio

Risk factor		N	Events	Model 1		Model 2	
				RR (95% CI)		RR (95% CI)	
<b>Physical Activity</b>							
	Inactive	95,221	112	1.00	(ref)	1.00	(ref)
	Insufficient	140,609	115	0.75	(0.58, 0.97)	0.87	(0.67, 1.14)
	Sufficient	232,613	160	0.57	(0.44, 0.72)	0.70	(0.54, 0.89)
<b>Sedentary Behaviour</b>							
	High	57,485	68	1.00	(ref)	1.00	(ref)
	Moderate	249,929	217	0.72	(0.55, 0.95)	0.90	(0.68, 1.90)
	Low	161,029	102	0.65	(0.48, 0.89)	0.87	(0.64, 1.20)
<b>Sleep</b>							
	Poor	14,520	17	1.00	(ref)	1.00	(ref)
	Moderate	201,135	181	0.75	(0.46, 1.24)	0.96	(0.58, 1.58)
	Good	252,788	189	0.66	(0.40, 1.08)	0.97	(0.59, 1.61)
<b>Diet</b>							
	Poor	75,264	62	1.00	(ref)	1.00	(ref)
	Moderate	186,893	140	0.83	(0.61, 1.12)	0.92	(0.68, 1.25)
	Good	206,286	185	0.85	(0.64, 1.14)	1.03	(0.77, 1.39)
<b>Alcohol</b>							
	Ex-drinker	16,257	29	1.00	(ref)	1.00	(ref)
	Above guideline	169,542	150	0.46	(0.31, 0.69)	0.62	(0.41, 0.93)
	Never drinker	19,522	25	0.79	(0.46, 1.35)	0.87	(0.50, 1.50)
	Within guideline	261,842	183	0.44	(0.30, 0.69)	0.60	(0.40, 0.89)
<b>Smoking</b>							
	Current	48,581	59	1.00	(ref)	1.00	(ref)
	Previous	162,990	183	0.66	(0.49, 0.89)	0.75	(0.55, 1.02)
	Never	256,872	145	0.45	(0.33, 0.61)	0.54	(0.39, 0.74)

Model 1: adjusted for age and sex; Model 2: adjusted for age, sex, socioeconomic status, ethnicity, BMI, cardiovascular disease, cancer, diabetes, hypertension, use of anti-hypertensive medication, use of corticosteroids, chronic lung/respiratory disease, liver diseases, diabetes, end-stage renal disease, and immune disorders/HIV and mutually adjusted for each lifestyle risk factor; Physical Activity = [Inactive = 0 min of moderate to vigorous physical activity (mvpa)]; Insufficient = 1-149 min of mvpa; Sufficient  $\geq$  150 min of mvpa; Sedentary Behaviour = [High > 7 hrs; Moderate = 4-7 hrs; Low <4 hrs]; Sleep = [Poor index  $\leq$  1 sleep score; Moderate index 2-3 sleep score; Good index > 3 sleep score]; Diet = [Poor quality = 0 diet score; Moderate quality = 1 diet score; Good quality = 2 diet score]. Alcohol = [Above guideline  $\geq$ 14 units; 1 unit = 8 g of alcohol].

Figure 1 caption: Healthy lifestyle index hazard ratio for infectious diseases and pneumonia mortality. Models are adjusted for age, sex, socioeconomic status, ethnicity, BMI, cardiovascular disease, cancer, diabetes, hypertension, use of anti-hypertensive medication, use of corticosteroids, chronic lung/respiratory disease, liver diseases, diabetes, end-stage renal disease, and immune disorders/HIV. The original combined lifestyle behaviour scores ranged from 0-12. This score has been re-classified as follows: scores 0 to 4 = least Healthy group; score of 5 = 6<sup>th</sup> Healthiest group; score of 6 = 5<sup>th</sup> Healthiest group; score of 7 = 4<sup>th</sup> Healthiest group; score of 8 = 3<sup>rd</sup> Healthiest group; score of 9 = 2<sup>nd</sup> Healthiest group; scores 10 to 12 = Healthiest group.

Figure 2 caption: Healthy lifestyle index risk ratio for COVID-19 mortality. Models are adjusted for age, sex, socioeconomic status, ethnicity, BMI, cardiovascular disease, cancer, diabetes, hypertension, use of anti-hypertensive medication, use of corticosteroids, chronic lung/respiratory disease, liver diseases, diabetes, end-stage renal disease, and immune disorders/HIV. The original combined lifestyle behaviour scores ranged from 0-12. This score has been re-classified as follows: scores 0 to 4 = least Healthy group; score of 5 = 6<sup>th</sup> Healthiest group; score of 6 = 5<sup>th</sup> Healthiest group; score of 7 = 4<sup>th</sup> Healthiest group; score of 8 = 3<sup>rd</sup> Healthiest group; score of 9 = 2<sup>nd</sup> Healthiest group; scores 10 to 12 = Healthiest group.

Figure 1




Figure 2

# COVID-19

